Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical TrialRami Kantor, Susan H. Eshleman, Khuanchai Supparatpinyo et al.|Clinical Infectious Diseases|2015Cited by 80
Improved Neuropsychological and Neurological Functioning Across Three Antiretroviral Regimens in Diverse Resource-Limited Settings: AIDS Clinical Trials Group Study A5199, the International Neurological StudyK. Robertson, Aspara Nair, Hongyu Jiang et al.|Clinical Infectious Diseases|2012Cited by 61
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settingsKevin Robertson, Pim Brouwers, Johnstone Kumwenda et al.|Journal of NeuroVirology|2011Cited by 45
The rate of bone loss slows after 1–2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (<scp>START</scp>) bone mineral density substudyAndrew Carr, Birgit Grund, AV Schwartz et al.|HIV Medicine|2019Cited by 19
Pro-Inflammatory Alterations of Circulating Monocytes in Latent Tuberculosis InfectionManuel G. Feria, Moisés A. Huamán, Cecilia Chang et al.|Open Forum Infectious Diseases|2022Cited by 18